Neuralink, Elon Musk’s brain-computer interface company, announced on May 25 (local time) that it had received approval from the U.S. Food and Drug Administration (FDA) to launch its first-in-human clinical study.
Neuralink stated that its clinical trials have not yet begun recruiting participants and that more relevant information will be released soon.
